Results 201 to 210 of about 93,929 (247)

AI fragmentation-based optimization of Sorafenib derivatives targeting VEGFR2 for angiogenesis-related pathologies: a structure-based in-silico study. [PDF]

Sci Rep
Inan D, Karageçili S, Ali N.
europepmc   +1 more source

Nutrient Restriction Improves the Therapeutic Efficacy of Sorafenib by Inducing Ferroptosis via the NRF2/HO-1/GPX4 Pathway in Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Chen X, Chen K, Xu Z, Shou K, Jin C, Zheng Z, Chen K.   +6 more
europepmc   +1 more source

Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor-Resistant Patients in Clear Cell Renal Cell Carcinoma. [PDF]

Cancer Res Commun
Abdullah H, Um IH, Stewart GD, Jeong CW, Kwak C, Moon KC, Laird A, Frangou E, Eisen T, Meade A, Harrison DJ.   +10 more
europepmc   +1 more source

The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China. [PDF]

Front Pharmacol
Ma L, Zhu T, Duan J, Huang N, Zhang Z.
europepmc   +1 more source

Correction: Improving the therapeutic efficacy of sorafenib for hepatocellular carcinoma by repurposing disulfiram. [PDF]

Front Oncol
Zhang G, Wang Y, Fuchs BC, Guo W, Drum DL, Erstad DJ, Shi B, DeLeo AB, Zheng H, Cai L, Zhang L, Tanabe KK, Wang X.   +12 more
europepmc   +1 more source

Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial. [PDF]

Liver Cancer
Chan SL, Kaseb AO, Alexander L, Meng X, Ryan K, Shi W, Vogel A.   +6 more
europepmc   +1 more source

Transcriptomic Analysis Reveals an NRF2-Mediated Redox and Metabolic Reprogramming in Sorafenib-Resistant Hepatocellular Carcinoma Cells. [PDF]

BioTech (Basel)
Michilli A, Bassi C, Moshiri F, De Siena B, Marinaro R, Callegari E, Negrini M, Sabbioni S.   +7 more
europepmc   +1 more source

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. [PDF]

Ther Adv Med Oncol
Qi H, Huang Y, Zhang W, Li J, Wang T, Ying Y, Chen B, Miao F, Li Q.   +8 more
europepmc   +1 more source

Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma. [PDF]

Clinics (Sao Paulo)
Bo W, Wang Z, Dong X, Zou J.
europepmc   +1 more source

Case Report: Sorafenib-induced rhabdomyolysis in a post-transplant patient with acute myeloid leukemia. [PDF]

Front Oncol
Ke L, Cao L, Li S, Zhou Z, Zheng P.
europepmc   +1 more source